STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

Galectin Therapeutics (GALT) director reports option exercises and stock sales

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Galectin Therapeutics director Jack W. Callicutt reported option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on August 29, 2025. On December 12, 2025, he exercised stock options to acquire 19,793 common shares at an exercise price of $4.16 and sold 19,793 shares at a weighted average price of $6.274, leaving 11,206 shares held directly.

On December 15, 2025, he exercised options to acquire 8,417 shares at $4.16 and sold 8,417 shares at a weighted average price of $6.3, with 11,206 Galectin Therapeutics shares shown as beneficially owned directly after the reported transactions. The options exercised have a $4.16 exercise price, vested 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.

Positive

  • None.

Negative

  • None.
Insider Shlevin Harold H.
Role Director
Sold 28,210 shs ($177K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 8,417 $0.00 --
Exercise Common Stok 8,417 $4.16 $35K
Sale Common Stock 8,417 $6.30 $53K
Exercise Stock Option (right to buy) 19,793 $0.00 --
Exercise Common Stock 19,793 $4.16 $82K
Sale Common Stock 19,793 $6.274 $124K
Holdings After Transaction: Stock option (right to buy) — 0 shares (Direct); Common Stok — 19,623 shares (Direct); Common Stock — 11,206 shares (Direct); Stock Option (right to buy) — 53,417 shares (Direct)
Footnotes (1)
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shlevin Harold H.
(Last) (First) (Middle)
C/O GALECTIN THERAPEUTICS INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
(Street)
NORCROSS GA 30071
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/12/2025 M(1) 19,793 A $4.16 30,999 D
Common Stock 12/12/2025 S(1) 19,793 D $6.274(2) 11,206 D
Common Stok 12/15/2025 M(1) 8,417 A $4.16 19,623 D
Common Stock 12/15/2025 S(1) 8,417 D $6.3(2) 11,206 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $4.16 12/12/2025 M(1) 19,793 12/31/2018(3) 05/22/2028 Common Stock 16,790 $0 53,417 D
Stock option (right to buy) $4.16 12/15/2025 M(1) 8,417 12/31/2018(3) 05/22/2028 Common Stock 8,417 $0 0 D
Explanation of Responses:
1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
2. The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.
Jack W. Callicutt, by power of attorney 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Galectin Therapeutics (GALT) report for Jack W. Callicutt?

The report shows that director Jack W. Callicutt exercised stock options and sold Galectin Therapeutics common shares in December 2025 under a Rule 10b5-1 trading plan adopted on August 29, 2025.

How many Galectin Therapeutics (GALT) shares did Jack W. Callicutt sell and at what prices?

On December 12, 2025, he sold 19,793 shares at a weighted average price of $6.274. On December 15, 2025, he sold 8,417 shares at a weighted average price of $6.3. The sales occurred in multiple transactions at prices ranging from $6.25 to $6.40.

What stock options did the Galectin Therapeutics (GALT) director exercise?

He exercised stock options with a $4.16 exercise price to buy 19,793 shares on December 12, 2025 and 8,417 shares on December 15, 2025. These options vest 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.

How many Galectin Therapeutics (GALT) shares does Jack W. Callicutt own after the reported transactions?

After the reported December 2025 transactions, Jack W. Callicutt is shown as beneficially owning 11,206 Galectin Therapeutics common shares directly.

Were Jack W. Callicutt’s Galectin Therapeutics (GALT) trades made under a Rule 10b5-1 plan?

Yes. The explanation notes that the reported transactions were made under a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as described in a prior quarterly report.

What is Jack W. Callicutt’s relationship to Galectin Therapeutics (GALT)?

Jack W. Callicutt is identified in the report as a director of Galectin Therapeutics Inc. and the form is filed by one reporting person.